

SCHEDA 1

Argomento: "Radiofarmaci basati su chelanti per radiometalli"

Domanda 1

Esporre la sintesi del radiofarmaco gallio-68-PSMA-11

Argomento "Preparazione e controllo di qualità dei radiofarmaci"

Domanda 2

Principi di funzionamento del generatore germanio-68/gallio-68

Informatica

Domanda 3

Che cos'è un sistema RIS/PACS?

Inglese

Domanda 4

Leggere e tradurre il seguente brano:

68Ga-DOTATOC is useful for evaluating the presence and extent in disease for staging and restaging and for assisting in treatment decision making for patients with NET. It is also effective in locating the site of an unknown primary in NET patients who present with metastatic NET, but no known primary tumor. It also appears to be more accurate than 111In-octreotide. Although 68Ga-DOTATOC would seem to be useful in evaluating patients with suggestive symptoms and biomarker findings, it does not perform well in this setting and has low yield. Overall, it appears to be an excellent imaging agent to assess patients with known NET and frequently leads to a change in management.

SCHEDA 2

Argomento: "Radiofarmaci basati su chelanti per radiometalli"

Domanda 1

Differenti preparazioni del radiofarmaco gallio-68-DOTATOC.

Argomento "Preparazione e controllo di qualità dei radiofarmaci"

Domanda 2

Controlli di qualità delle preparazioni radiofarmaceutiche semplici e estemporanee

Informatica

Domanda 3

Che cos'è il formato DICOM e a che cosa serve?

Inglese

Domanda 4

Leggere e tradurre il seguente brano:

Treatment of somatostatin receptor-positive tumors with radiolabeled somatostatin analog is a promising option. Several phase I and phase II studies done at a few centers around the world reported encouraging results with [^{90}Y -DOTA-Tyr 3]-octreotide (DOTATOC) and/or [(177)Lu-DOTA-Tyr 3 -Thr 8]-octreotate (DOTATATE). The current article is a selective review of patients who were treated mainly with ^{90}Y -DOTATOC after failure with conventional therapy. The aim is to provide an updated comprehensive evaluation of the overall effectiveness of ^{90}Y -DOTATOC therapy in patients with somatostatin-positive tumors.